艾克司单抗与恶性肿瘤:25项随机临床试验汇总分析
该汇总分析纳入25项随机临床试验,评估银屑病、银屑病关节炎或中轴型脊柱关节炎患者长期使用艾克司单抗的恶性肿瘤发生率。结果显示恶性肿瘤发生率低且随时间稳定,标准化发病比接近或低于美国一般人群。
要点
- 艾克司单抗长期治疗中恶性肿瘤发生率低,1年间隔发生率≤1.2/100患者年且保持稳定。
- 银屑病、银屑病关节炎和中轴型脊柱关节炎的标准化发病比均接近或低于1。
- 安全性特征支持艾克司单抗在上述适应症中的长期使用。
核心结论
- 艾克司单抗在银屑病、银屑病关节炎和中轴型脊柱关节炎患者中长期使用,恶性肿瘤发生风险与既往报告一致,标准化发病比与美国一般人群相似。
研究设计与样本
- 多中心全球汇总分析,纳入25项随机临床试验中接受至少1剂艾克司单抗治疗的患者,银屑病随访5年,银屑病关节炎和中轴型脊柱关节炎随访3年。
- 主要分析于2021年3月(银屑病关节炎)和2022年3月(银屑病和中轴型脊柱关节炎)进行。
主要发现
- 银屑病患者中141例(2.0%)报告恶性肿瘤,发生率0.8/100患者年(95% CI 0.7-0.9)。
- 银屑病关节炎患者中15例(1.1%)报告恶性肿瘤,发生率0.7/100患者年(95% CI 0.4-1.1)。
- 中轴型脊柱关节炎患者中9例(1.0%)报告恶性肿瘤,发生率0.4/100患者年(95% CI 0.2-0.8)。
- 1年间隔恶性肿瘤发生率低(≤1.2/100患者年)且随时间保持恒定。
- 标准化发病比(95% CI):银屑病0.89(0.71-1.08),银屑病关节炎0.49(0.13-0.85),中轴型脊柱关节炎1.07(0.37-1.77)。
临床怎么用
- 长期使用艾克司单抗治疗银屑病、银屑病关节炎或中轴型脊柱关节炎时,恶性肿瘤风险低且与一般人群相似,支持临床长期应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Assessing malignant neoplasm risk among patients with long-term biologic exposure is of interest. This study provides insight into the risk of malignant neoplasm among patients with psoriasis (PsO), psoriatic arthritis (PsA), or axial spondyloarthritis (axSpA) who received ixekizumab (IXE) over time. OBJECTIVE: To determine the incidence of malignant neoplasms among patients with PsO, PsA, or axSpA who received long-term (up to 6 years) IXE treatment, and to compare the recorded incidences (excluding nonmelanoma skin cancer) with those observed in the US general population. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, global pooled analysis examined patient data from 25 randomized clinical trials (RCTs) in patients with PsO, PsA, or axSpA receiving at least 1 dose of IXE over 5 years (PsO) or 3 years (PsA and axSpA). Eligibility criteria varied across the 25 RCTs, but most of the patients were naive to biologic treatments. The primary analysis was performed in March 2021 (PsA) and March 2022 (PsO and axSpA). INTERVENTION: Long-term treatment with IXE. MAIN OUTCOMES AND MEASURES: Incidence rates of malignant neoplasms and standardized incidence ratios (SIRs). RESULTS: The mean age across the 3 indications was 45.9 years; most patients in the PsO and axSpA cohorts were male (4696/6892 [68.1%] and 650/932 [69.7%], respectively), whereas the proportion of male to female patients in the PsA cohort was largely balanced (679/1401 [48.5%] vs 722/1401 [51.5%], respectively). The study included 6892 patients with PsO, 1401 patients with PsA, and 932 patients with axSpA, representing a cumulative exposure to IXE of 22 371.1 patient-years (PY) (18 025.7 PY for PsO, 2247.7 PY for PsA, and 2097.7 PY for axSpA). Malignant neoplasms were reported among 141 patients with PsO (2.0%; incidence rate [IR], 0.8 per 100 PY [95% CI, 0.7-0.9]), 15 patients with PsA (1.1%; IR, 0.7 per 100 PY [95% CI, 0.4-1.1]), and 9 patients with axSpA (1.0%; IR, 0.4 per 100 PY [95% CI, 0.2-0.8]). IRs of malignant neoplasms at 1-year intervals remained low (≤1.2 per 100 PY) and constant over time. SIRs with 95% CIs were below or near 1 (PsO, 0.89 [95% CI, 0.71-1.08]; PsA, 0.49 [95% CI, 0.13-0.85]; axSpA, 1.07 [95% CI, 0.37-1.77]). CONCLUSIONS AND RELEVANCE: This pooled analysis of 25 RCTs demonstrated that the safety profile of IXE supports long-term use in patients with PsO, PsA, or axSpA. This is evidenced by incidences of malignant neoplasms consistent with previous reports, and with SIRs of malignant neoplasms across indications similar to the US general population.
引用
- Merola JF, Papp KA, Deodhar A, et al. Ixekizumab and Malignant Neoplasms: A Pooled Analysis of Data From 25 Randomized Clinical Trials. JAMA Dermatol. 2025. PMID: 40632525. doi:10.1001/jamadermatol.2025.2056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。